# Herbolea Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/herbolea-biotech

- Industry: Biotechnology
- Headquarters: Florence, Italy
- Website: www.herbolea.com
- Total disclosed funding: $5.8M
- Latest round: Series A (Oct 26, 2021)
- Investors on record: 1

## About

Herbolea Biotech is an innovative company focused on extracting and purifying bioactive compounds from botanicals, utilizing patented technologies to deliver high-quality, solvent-free plant-based extracts for various industries.Founded in 2017 in Florence, Italy, Herbolea Biotech specializes in extracting bioactive compounds from botanicals. The company has not disclosed any major pivots or changes in its business strategy. Giovanni Del Greco serves as the CEO. The company raised EUR 5 million in Series A funding on October 26, 2021, led by Óskare Capital, bringing the total amount raised to EUR 5 million.Herbolea specializes in the extraction, concentration, and purification of bioactive compounds from various botanicals, utilizing innovative and patented technologies such as BIO-HERBOLYSIS™, HYDROCAN™, and DISTILLAC™. These processes leverage natural, solvent-less methods, ensuring that the final products contain 0% organic solvents and harmful substances, focusing instead on delivering high-quality, plant-based extracts. The company's solutions cater to a diverse customer base in markets including cosmetics, food, nutraceuticals, and pharmaceuticals, with a commitment to serving industry leaders worldwide. Herbolea's equipment is currently deployed in eight countries, indicating a strong global footprint that supports its expansion into additional markets.In 2023, Herbolea Biotech reported a revenue of EUR 1,760,065.90, with an EBITDA of EUR -89,744.60. The company operates on a business-to-business (B2B) model, servicing manufacturers in various industries with its patented extraction technologies and high-quality botanical products. Transactions are structured through direct sales agreements, positioning Herbolea's offerings as premium solutions within the market.Following its Series A funding of EUR 5 million on October 26, 2021, led by Óskare Capital, Herbolea Biotech plans to utilize this funding to accelerate growth, expand its team, and enhance access to key markets, particularly in the US. The company is also focusing on upcoming product launches and aims to extend its reach into new geographic regions to support its growth strategy.

## Funding rounds

- Series A, Oct 26, 2021, $5.8M — Oskare Capital

## Investors

- Oskare Capital (https://capitalatlas.ai/funds/oskare-capital) — Series A